This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Drying Stimulus Tap Is Sore Spot for Tech Stocks

NEW YORK (TheStreet) -- The drying stimulus tap rather than stretched valuations has been the trigger for recent selling in tech and biotech shares, some managers argue, claiming this makes another tech sector crash unlikely.

Stocks facing pressure in the current market rout are also those with blue-sky stories, or companies facing a "long duration" before earnings justify their stock prices. Many of these rode market momentum last year and are being ditched in favor of value stories.

ING U.S. Investment Management noted clear downside for many stocks after confirmation from Federal Reserve minutes this week that rates will likely rise around mid-2015. "A tiny increase in the expectation of a rate rise a year and a half in the future is having an enormous impact on these long duration stocks," chief market strategist Douglas Cote told clients.

The investment manager pointed to sectors such as biotech, Internet retail, semiconductor equipment and health care technology stocks as the most vulnerable.

Social media and biotech companies were displaying their volatility on Friday. Twitter (TWTR) was more than 2% lower in afternoon trade after shedding an eye-watering 14% in the past fortnight, while Facebook (FB) was gaining 0.34% after shedding more than 5% on Thursday and jumping 7.25% on Wednesday. Biotech company Gilead Sciences (GILD) was popping 3.94% after diving 7.32% on Thursday.

But several managers said there is little evidence of stretched valuations in the tech sector, arguing against comparisons to the tech
bubble of 2000.

Capital Economics' chief markets economist,John Higgins, noted that in March 2000 -- the month in which technology shares peaked -- the price/estimated operating earnings ratio of the S&P 500 biotech index at 46 was more than twice its current level of about 20. The valuation of the IT sector was nearly four times as high.

"The key reasons we expect equities to struggle are dwindling fuel from the Fed and cyclical pressure on profit margins, rather than stretched valuations," Higgins said. He is forecasting a year-end level of 1,900 for the S&P, close to its current level. Others dismiss conventional financial metrics for sectors such as social media, pointing to the fickle drivers of earnings in the industry.

Many traders are pessimistic on the near-term outlook. "This (market move downward) needs to be recaptured sooner rather than later and has the potential to last three to five days," Greywolf Execution chief market strategist Mark Newton said. "Fewer indices are hitting new high territory globally and the price structure (of the U.S. market) is getting worse and worse and worse."

-- By Jane Searle in New York

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,001.22 -38.27 -0.22%
S&P 500 1,988.40 -3.97 -0.20%
NASDAQ 4,538.5510 +6.4470 0.14%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs